688105.SS
688105.SS
CNE100004ZK3
NANJING VAZYME BIOTECH CO LTD
Loading chart...

Company Profile

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real-time PCR (qPCR), one-step RT-PCR/RT-qPCR, nucleic acid electrophoresis, genome editing techniques, isothermal amplification, and instant granules; and cell and protein research reagents. It also provides NGS library preparation reagents, such as DNA sequencing, RNA sequencing, target capture sequencing, epigenetics, magnetic beads, NGS library quantification, and single-cell sequencing; reagents for biomedicine, including mRNA vaccine/drug key components, drug discovery tools, ELISA kits vaccine evaluation reagents, and semaglutide drug key components; instruments, including automated liquid handling workstation, automatic nucleic acid isolation system, real-time fluorescence quantitative PCR system, fluorescence quantimeter, and micro horizontal centrifuge; lab consumables for equipment comprising robotic pipette tips, robotic microwell plates, robotic deep well plates, and 96-well flat-bottom microplates; and monkeypox solutions. It serves research institutions, high-throughput sequencing service providers, molecular diagnostic reagent manufacturers, pharmaceutical companies, vaccine companies, contract research organizations (CROs), hospitals, and medical institutions. The company was founded in 2012 and is headquartered in Nanjing, China.

Related stocks

9606.HK
9606.HK • China
DUALITYBIO-B
182.7 HKD
2.13B USD 1Y -42.1%
600201.SS
600201.SS • China
JINYU BIO-TECHNOLOGY CO LTD
11.84 CNY
1.95B USD 1Y +21.7%
301207.SZ
301207.SZ • China
HUALAN VAC
19.88 CNY
1.79B USD 1Y +14.6%
301047.SZ
301047.SZ • China
SINO BIOLOGICAL
147.12 CNY
2.68B USD 1Y +99.2%
688520.SS
688520.SS • China
SINOCELLTECH GROUP LTD
36.22 CNY
2.55B USD 1Y -35.8%
688202.SS
688202.SS • China
SHANGHAI MEDICILON INC
104 CNY
2.09B USD 1Y +53.1%
1877.HK
1877.HK • China
JUNSHI BIO
17.65 HKD
2.31B USD 1Y -40.6%
2595.HK
2595.HK • China
GENFLEET-B
28.6 HKD
1.4B USD 1Y -21%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
56.6% p.a.
Max Drawdown (5Y)
-86.5%
Sharpe Ratio (5Y)
-0.34
Beta Factor
0.65
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Unprofitable business model: The company is currently generating net losses.
🔴 High valuation risk: Avg P/E of 72.0 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (56.6% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -86.5% in the extended horizon.
ende